Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease

Acta Neurologica Scandinavica

Volumn 135, Issue 2, 2017, Pages 252-256

  Han, S H ^a   Lee, J H ^b   Kim, S Y ^c   Park, K W ^d   Chen, C ^e   Tripathi, M ^f   Dash, A ^g   Kubota, N ^h  

^a Konkuk University Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^f ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^g TPS III   (India)

^h EISAI CO LTD   (Japan)

Author keywords

alzheimer disease; Asia; cognition; donepezil

Indexed keywords

DONEPEZIL; MEMANTINE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ANOREXIA; ASIAN; BODY WEIGHT DISORDER; CHRONOPHARMACOLOGY; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE PLUS CAREGIVER INPUT; COGNITION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEVERE IMPAIRMENT BATTERY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NAUSEA; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84959270735     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12571     Document Type: Note

References (9)

1. Prince M, Guerchet M, Prina M. Alzheimer's disease international. Policy brief for heads of government: The global impact of dementia 2013–2050. London: Alzheimer's Disease International, 2013.
2. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000;48:391–5.
3. Kaasinen V, Någren K, Järvenpää T et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002;22:615–20.
4. Farlow MR, Salloway S, Tariot PA et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32:1234–51.
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. ICH Harmonised Tripartite Guideline. Ethnic factors in the acceptability of foreign clinical data E5(R1). 5 February 1998. Available from: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html Accessed 30 December 2015.]
6. Han SH, Lee JH, Kubota N, Dash A. Efficacy and tolerability of donepezil 23 mg/d versus donepezil 10 mg/d in patients with moderate to severe AD in an Asian population: study 326 subanalysis. Alzheimer Dement 2014;10:P450–1.
7. ® prescribing information. August 2013.]
8. Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neurosci Ther 2013;19:294–301.
9. Bordier P, Lanusse S, Garrigue S et al. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging 2005;22:687–94.